LIVE
NVST
Envista Holdings Corporation · Healthcare - Dental Products
$25.91
+12.41% this month
VERSUS
⟷
COMPARE
DHR
Danaher Corporation · Healthcare - Life Science Tools & Diagnostics
$177.17
+6.06% this month
Scoreboard verdict
Across AI score, momentum, valuation, upside, operating margin
NVST
2
DHR
3
Comparison scoreboard
DHR LEADS 3/5AI Score
NVST 23.9
DHR ✓50.3
1Y Return
NVST ✓+39.23%
DHR -9.49%
Fwd P/E
NVST ✓15.65
DHR 19.47
Target Up.
NVST +20.70%
DHR ✓+34.56%
Op. Margin
NVST 9.87%
DHR ✓22.94%
Metrics last refreshed: 6/20/2026
Quick take
NVST vs DHR Stock Comparison: AI Score, Valuation, Performance and Upside
NVST (Envista Holdings) was spun off from DHR (Danaher) in 2019 with the dental products portfolio, while Danaher retained life science tools, diagnostics, and environmental — both companies use continuous improvement methodologies but at very different scales and in different healthcare subsectors. Danaher is a larger, more diversified platform; Envista is a focused dental products pure-play.
NVST vs DHR is focused dental products spinoff (Envista's implants and orthodontics) versus diversified healthcare and life science tools compounder (Danaher's bioprocessing, diagnostics, and DBS-powered acquisition platform) — parent versus child in life science tools and healthcare.
Live analysis · updated 6/20/2026
DHR holds the edge across 3 of 5 key metrics in this comparison. NVST leads on both 1-year return (+39.23%) and forward P/E (15.65x vs 19.47x for DHR), a relatively favorable combination of momentum and valuation. On fundamentals, NVST is growing revenue faster (14.40%), while DHR maintains the higher operating margin (22.94%) — a classic growth-versus-profitability split. Analyst consensus implies meaningfully more upside for DHR (+34.56%) than for NVST (+20.70%).
Normalized 1Y performance
NVST
DHR
Recent returns
NVST
DHR
Analyst price targets & sentiment
NVST · 12 analysts
STRONG BUYHOLDSTRONG SELL
Hold (2.6/5.0)
Price target range
analyst low$15.00
analyst mean$29.69
current price$25.91
+20.7% upside to analyst mean
DHR · 23 analysts
STRONG BUYHOLDSTRONG SELL
Strong Buy (1.4/5.0)
Price target range
analyst low$210.00
analyst high$310.00
analyst mean$242.35
current price$177.17
+34.6% upside to analyst mean
Who should consider this stock?
NVST may suit investors who:
- →Want focused dental products exposure through Nobel Biocare implants, Ormco orthodontics, and iTero intraoral scanners in the growing global dental market
- →Value Envista's path to independent profitability improvement as the company scales and optimizes operations following the Danaher spin-off
- →See dental implant and clear aligner market growth as structural tailwinds as aging populations and increasing dental aesthetics consciousness drive treatment volumes
DHR may suit investors who:
- →Want the Danaher Business System compounder with bioprocessing, diagnostics, and life science tools as the core platform — one of the most respected capital allocation track records in healthcare
- →Value Cytiva's bioprocessing recovery as a catalyst for Danaher's growth re-acceleration following the 2022-2024 biopharma inventory destocking cycle
- →Prefer diversified healthcare and life science exposure versus focused dental-only or pure diagnostic pure-plays
Performance & AI score
| Metric | NVST | DHR |
|---|---|---|
| AI score | 23.9 | 50.3 |
| AI rank | #3380 | #448 |
| Latest close | $25.91 | $177.17 |
| 1M return | +12.41% | +6.06% |
| 6M return | +18.58% | -20.42% |
| 1Y return | +39.23% | -9.49% |
$10,000 invested — hypothetical growth (dividends reinvested)
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | NVST | DHR |
|---|---|---|
| 1Y ago | $13.92K (+39.2%) started 2025-06-18 | $9.11K (-8.9%) started 2025-06-18 |
| 5Y ago | $6.06K (-39.4%) started 2021-06-18 | $7.86K (-21.4%) started 2021-06-21 |
| 10Y ago | $9.27K (-7.3%) started 2019-09-18 | $61.46K (+514.6%) started 2016-06-20 |
Hypothetical — past performance does not guarantee future results.
Valuation & upside potential
| Metric | NVST | DHR |
|---|---|---|
| Market cap | $4B | $127.47B |
| Trailing P/E | 60.00 | 34.84 |
| Forward P/E | 15.65 | 19.47 |
| Price/Sales | 1.27 | 5.89 |
| EV/Revenue | 1.61 | 5.71 |
| Analyst target | $29.69 | $242.35 |
| Target upside | +20.70% | +34.56% |
Growth, profitability & risk
| Metric | NVST | DHR |
|---|---|---|
| Revenue growth | 14.40% | 3.70% |
| Earnings growth | 130.00% | 9.80% |
| EPS growth | +130.00% | +9.80% |
| FCF margin | +7.70% | +18.44% |
| Operating margin | 9.87% | 22.94% |
| Profit margin | 2.41% | 14.89% |
| ROIC proxy | 2.21% | 7.08% |
| Return on equity | 2.21% | 7.08% |
| Dividend yield | N/A | 0.89% |
| Beta | 0.89 | 0.83 |
| Debt/equity | 51.61 | 37.17 |
| Current ratio | 2.44 | 1.87 |
| Quick ratio | 1.93 | 1.40 |
Drawdown & downside risk
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
1Y risk snapshot
NVST max drawdown25.97%
DHR max drawdown33.11%
NVST max wkly drop11.64%
DHR max wkly drop8.99%
5Y risk snapshot
NVST max drawdown71.00%
DHR max drawdown44.20%
NVST max wkly drop15.22%
DHR max wkly drop14.50%
10Y risk snapshot
NVST max drawdown71.00%
DHR max drawdown44.20%
NVST max wkly drop39.19%
DHR max wkly drop14.50%
Performance metrics by period
| Period | Metric | NVST | DHR |
|---|---|---|---|
| 1Y | Growth | +39.23% | -8.88% |
| CAGR | +39.26% | -8.89% | |
| Sharpe ratio | 0.93 | -0.35 | |
| Max drawdown | 25.97% | 33.11% | |
| Max daily drop | 10.27% | 5.40% | |
| Max wkly drop | 11.64% | 8.99% | |
| 5Y | Growth | -39.42% | -22.65% |
| CAGR | -9.54% | -5.01% | |
| Sharpe ratio | -0.22 | -0.21 | |
| Max drawdown | 71.00% | 44.20% | |
| Max daily drop | 10.27% | 9.73% | |
| Max wkly drop | 15.22% | 14.50% | |
| 10Y | Growth | -7.30% | +333.14% |
| CAGR | -1.12% | +15.80% | |
| Sharpe ratio | 0.06 | 0.46 | |
| Max drawdown | 71.00% | 44.20% | |
| Max daily drop | 23.19% | 9.73% | |
| Max wkly drop | 39.19% | 14.50% |
Business comparison
| Category | NVST | DHR |
|---|---|---|
| Company | Envista Holdings Corporation | Danaher Corporation |
| Sector | Healthcare | Healthcare |
| Industry | Medical Instruments & Supplies | Diagnostics & Research |
| Core business | Envista Holdings is a dental products company spun off from Danaher in 2019, offering dental implants, orthodontics (Ormco, iTero), and dental consumables through its Specialty Products & Technologies and Equipment & Consumables segments — serving dental practitioners globally. | Danaher is a global science and technology company providing instruments, reagents, and software for life science research (Cytiva for bioprocessing, Leica for microscopy), diagnostics (Radiometer, HemoCue), and environmental and applied solutions — operating through an acquisition and continuous improvement methodology known as the Danaher Business System (DBS). |
| Investor focus | Investors track Envista's implant market share, iTero intraoral scanner adoption, clear aligner treatment attachment rate, organic revenue growth, and the company's ability to improve operating margins as an independent company after the Danaher spin-off. | Investors track Danaher's bioprocessing revenue (Cytiva — a key biotech/biopharma tool supplier), core revenue growth, operating margin expansion through DBS, and capital allocation between organic investment and M&A. |
NVST strengths
- →Strong dental implant brands (Nobel Biocare, Implant Direct) and orthodontic technology (Ormco, iTero intraoral scanner) give Envista positions in premium segments of the dental market
- →Clear aligner market integration — iTero scanners are used in Invisalign workflows, creating a relationship with Align Technology and a foothold in the growing clear aligner orthodontic market
- →Dental procedures are generally non-discretionary maintenance expenditures rather than purely elective, providing demand resilience through economic cycles
DHR strengths
- →Danaher Business System (DBS) — the proprietary continuous improvement methodology based on Toyota Production System principles — consistently improves acquired company operating performance, creating compounding value from acquisitions
- →Bioprocessing franchise (Cytiva) provides mission-critical equipment and consumables for biopharmaceutical drug manufacturing — an essential position in the biopharma supply chain
- →Diversified platform across life sciences, diagnostics, and water quality provides multiple exposure to large and growing markets with different cyclical characteristics
Risks to watch — NVST
- →Envista operates independently after the Danaher spin-off and must demonstrate it can grow and improve margins without Danaher's operational system (DBS) and balance sheet support
- →Dental implant market competition from Straumann, Envista's Nobel Biocare, and others intensifies as market leaders compete on pricing, technology, and distribution
- →Consumer spending on elective dental procedures (cosmetic work, implants) can be deferred during economic downturns, making revenue timing sensitive to consumer confidence
Risks to watch — DHR
- →Bioprocessing inventory destocking cycle (2022-2024) significantly reduced Cytiva revenue as biopharma companies drew down COVID-era inventory excesses — recovery timing is critical for Danaher's growth re-acceleration
- →Large acquisitions require successful DBS integration to achieve value — poor acquisition choices or integration execution can be value-destructive despite the strong DBS system
- →Life science research spending is tied to NIH and private biopharma R&D budgets, which can fluctuate with government budget changes and biopharma industry spending cycles
Frequently asked questions
Free public comparison
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Related comparisons
More comparisons
Browse all 1,000 comparisons →